Pfizer announces FDA approval of XELJANZ® (tofacitinib) and XELJANZ® XR for PsA
Pfizer announced the FDA has approved XELJANZ® 5 mg twice daily and XELJANZ® XR (tofacitinib) extended release 11 mg once daily for treatment of adult patients with active psoriatic arthritis who have had an inadequate response or intolerance to methotrexate or other DMARDs. December 14, 2017